0001209191-24-004402.txt : 20240305
0001209191-24-004402.hdr.sgml : 20240305
20240305170456
ACCESSION NUMBER: 0001209191-24-004402
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20240301
FILED AS OF DATE: 20240305
DATE AS OF CHANGE: 20240305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Monahan Joseph
CENTRAL INDEX KEY: 0001861790
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37581
FILM NUMBER: 24722041
MAIL ADDRESS:
STREET 1: C/O ACLARIS THERAPEUTICS, INC.
STREET 2: 701 LEE ROAD, SUITE 103
CITY: WAYNE
STATE: PA
ZIP: 19087
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc.
CENTRAL INDEX KEY: 0001557746
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 460571712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 701 LEE ROAD
STREET 2: SUITE 103
CITY: WAYNE
STATE: PA
ZIP: 19087
BUSINESS PHONE: 484-324-7933
MAIL ADDRESS:
STREET 1: 701 LEE ROAD
STREET 2: SUITE 103
CITY: WAYNE
STATE: PA
ZIP: 19087
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-03-01
0
0001557746
Aclaris Therapeutics, Inc.
ACRS
0001861790
Monahan Joseph
C/O ACLARIS THERAPEUTICS, INC.
701 LEE ROAD, SUITE 103
WAYNE
PA
19087
0
1
0
0
Chief Scientific Officer
0
Common Stock
2024-03-01
4
M
0
50000
A
184641
D
Common Stock
2024-03-01
4
F
0
14569
1.24
D
170072
D
Common Stock
2024-03-01
4
M
0
10925
A
180997
D
Common Stock
2024-03-01
4
F
0
3183
1.24
D
177814
D
Common Stock
2024-03-02
4
M
0
12500
A
190314
D
Common Stock
2024-03-02
4
F
0
3531
1.24
D
186783
D
Common Stock
193
I
By Spouse
Restricted Stock Units
2024-03-01
4
M
0
50000
0.00
D
Common Stock
50000
50000
D
Restricted Stock Units
2024-03-01
4
M
0
10925
0.00
D
Common Stock
10925
21850
D
Restricted Stock Units
2024-03-02
4
M
0
12500
0.00
D
Common Stock
12500
0
D
Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.
The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.
The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.
Exhibit 24.1 - Power of Attorney
/s/ Matthew Rothman, Attorney-in-Fact
2024-03-05
EX-24
2
poa.txt
POA DOCUMENT
Exhibit 24.1
POWER OF ATTORNEY
(For Executing Form ID and Forms 3, 4 and 5)
Know all by these presents, that the undersigned hereby constitutes and
appoints each of Neal Walker, Kevin Balthaser and Matthew Rothman of Aclaris
Therapeutics, Inc. (the "Company") and Mark Ballantyne, David Brinton and Robin
Lee of Cooley LLP, the undersigned's true and lawful attorneys-in-fact and
agents to:
(1) Prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the Securities and Exchange Commission (the "SEC") a Form ID,
Uniform Application for Access Codes to File on EDGAR, including amendments
thereto, and any other documents necessary or appropriate to obtain codes and
passwords enabling the undersigned to make electronic filings with the SEC of
reports required by Section 16(a) of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), or any rule or regulation thereunder;
(2) Prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the SEC Forms 3, 4 and 5 (including amendments thereto and joint
filing agreements in connection therewith) in accordance with Section 16(a) of
the Exchange Act and the rules thereunder in the undersigned's capacity as an
officer, director or beneficial owner of more than 10% of a registered class of
securities of the Company;
(3) Do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to prepare and execute any such Form 3, 4 or 5
(including amendments thereto and joint filing agreements in connection
therewith) and file such forms with the SEC and any stock exchange,
self-regulatory association or any similar authority; and
(4) Take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required of the undersigned, it being
understood that the documents executed by the attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as the attorney-in-fact may approve in the
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney in fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney in fact, or such attorney
in fact's substitute or substitutes, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and powers herein granted. The
undersigned acknowledges that the foregoing attorneys-in-fact, and their
substitutes, in serving in such capacity at the request of the undersigned, are
not assuming (nor is the Company assuming) any of the undersigned's
responsibilities to comply with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the Company and the foregoing attorneys-in fact or (c) as to any
attorney-in-fact individually, until such attorney-in-fact is no longer employed
by the Company or Cooley LLP, as applicable.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of the date written below.
Date: 2/29/2024
By: /s/ Joe Monahan
Joseph Monahan